

# Prioritisation of threats and medical countermeasures

Agnes Molnar, Acting Head of Unit, HERA 02


Broad spectrum antiviral workshop 22-23, November 2022



## **Intelligence gathering**

#### PREPAREDNESS

#### Threat assessments and intelligence gathering



## **Threat prioritisation**

- Aim: identify 3 serious cross-border health threats to guide HERA's action on monitoring, research and development, production, procurement and stockpiling of MCMs
  - 'All hazards approach' identification of threat categories, using publicly available data/lists
  - Selection of priority threat category considering burden on health, mode of transmission, risk of spreading, but also the availability of prophylaxis/treatment
  - Extensive consultation and alignment with Member States' priorities, EU and international stakeholders

this category includes largely, but not exclusively, **respiratory RNA viral families**: Arena-, Bunya-, Corona-, Flavi-, Filo-, Orthomyxo-, Paramyxo-, Picorna-, Pox- and Togaviridae viral families



AMR

Agents with


pandemic potential

CBRN



## **Development of MCM list**

The list of critical MCMs will include high-priority MCMs for development, including next generation vaccines, broad spectrum antivirals, antibiotics against AMR, other MCMs in cooperation with MS, EMA and ECDC



#### PREPAREDNESS MODE

- HERA will draw a broad list of critical MCMs
- HERA will gather intelligence on selected critical MCMs
- HERA will identify gaps (where authorised treatments are not available) and needs in terms of market interest on MCMs for a short list for R&D

#### **CRISIS MODE – Council Regulation on the emergency framework**

- HERA will activate emergency research plans for R&D (incl. clinical trials) of novel/repurposed MCMs
- HERA will support production and deployment of (un)authorised MCMs



## **Scope of the MCM list**

HERA is working with Member States on a catalogue of MCMs and MCM categories that will be used as a basis for the MCM prioritisation

ANTIINFECTIVES FOR SYSTEMIC USE <sup>1</sup>	whole virus		
Antivirals	Yellow fever live attenuated vaccine		
Baloxavir marboxil (Xofluza)	Influenza vaccines		
Brincidofovir	Variola minor vaccine		
Inmazeb	Venezuelan equine encephalitis virus vaccine		
Remdesivir (Veklury)	Junin mammarenavirus vaccine		
Ribavirin	Immune sera and immunoglobulins		
Tecovirimat	mAb		
Zanamivir (Dectova)	Ronapreve (casirivimab and imdevimab )		
Variola minor antiviral	Vaccinia Immune Globulin Intravenous		
Neuraminidase inhibitors	immunoglobulins Ebola		
Vaccines	Tick-borne encephalitis immunoglobulins		
ACAM2000	Regkirona		
AstraZeneca	IN-VITRO DIAGNOSTICS		
Comirnaty	Antibody tests		
Dengvaxia	antibodies CCHF		
Imvanex/Imvamune	antibodies MERS-CoV		
Ixiaro	antibodies SARS-CoV-2		
Jcovden	Antigen tests		
LC16M8	antigen CCHF		
Spikevax	antigen SARS-CoV-2		
Vaxzevria	ELISA tests		
Ervebo (rVSVAG-ZEBOV-GP, live)	ELISA Margburg virus		
combination Ad26.ZEBOV-GP [recombinant] and	PCR tests		

#### Threat specific MCMs

#### **Horizontal MCMs**

PPI	E
Res	spiratory protection
Par	ticulate respirators
Eye	ewear protection
Go	ggles
Pro	tective glasses
Cov	veralls
He	ad and face protection
Fac	e shields
Cap	05
Но	ods
He	ad covers hairnets
Ot	ner protection
Glo	ves
Арі	rons
Pro	tecting clothing/scrubs
Sho	pe protective (covers, <u>overboots</u> , overshoes)
ОТ	HER IN VITRO DIAGNOSTICS
Rea	agent and test kits
CRI infl	P tests and <u>and</u> other markers of ammation tests
	od grouping
Oth	ner Clinical chemistry
Imr	nunochemistry

Reagents, including lysis burlets		
Other plastic consumables, pipette tips		
MEDICAL DEVICES		
Devices for imaging		
Computed tomography (CT) scanners		
Ultrasound machines, and accessories		
Electrocardiograph, and accessories		
Fiberscopes		
Devices for suture		
Surgical sutures		
Mechanical sutures		
Clips		
Devices for dermatological and		
ophthalmological use		
Wound dressings		
Other devices for sores and ulcers		
Surgical instruments		
Various		
ANTISEPTICS		
chlorhexidine		
ethanol		
Povidone iodine		
DISINFECTANTS		
alcohol based hand rub		
chlorine base compound		

Reagents, including lysis buffers

## Establishing the list of critical MCMs

refine the listing methodology

complete the list with MCM and promising products in the pipeline

identify the most critical MCM in each category


assess availability and accessibility of the most critical MCMs

consider additional information available at national or EU level

develop list of critical MCMs

Commiss

### **End-to-end support**



## EU4HEALTH & HORIZON EUROPE

to support investments into R&D of innovative MCMs for cross-border health threats

#### JOINT PROCUREMENT & rescEU

European Commission

planned purchases for stockpiling donations and own use

## Thank you



© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the <u>CC BY 4.0</u> license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.



Slide xx: element concerned, source: e.g. Fotolia.com; Slide xx: element concerned, source: e.g. iStock.com